Home
Amgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture

Amgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture

Today’s Highlights
,
April 10, 2019

Amgen and UDB Granted FDA Approval of Evenity™

Amgen (AMGN) and UCB Pharmaceuticals (This content is for paid subscribers.

Please click here to subscribe or here to log in.

Other Articles